“The markets are dead!”: Emerita Resources (EMO.V) shows otherwise with massive upside coming
Lithium Ionic (LTH.V) is up 50% in 3 months, and is moving toward production
Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Why Prospera Energy (PEI.V) might be a transformational investment opportunity in Canadian oil & gas
Sparc AI (SPAI.C) completes development of drone advanced target acquisition system
BioVaxys Technology (BIOV.C) announced today that the US Food and Drug Administration (FDA) has reviewed its pre-IND request for a Type B review of the Company’s Covid-T™ program. Read full article here: https://equity.guru/2021/06/14/biovaxys-technology-biov-c-receives-positive-fda-response/
